-
1
-
-
78649391451
-
Improving outcomes for patients with diffuse large B-cell lymphoma
-
Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin. 2010;60:393-408.
-
(2010)
CA Cancer J Clin.
, vol.60
, pp. 393-408
-
-
Flowers, C.R.1
Sinha, R.2
Vose, J.M.3
-
2
-
-
33745982067
-
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
-
Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121-7.
-
(2006)
J Clin Oncol.
, vol.24
, pp. 3121-3127
-
-
Habermann, T.M.1
Weller, E.A.2
Morrison, V.A.3
-
3
-
-
38549147027
-
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60)
-
Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105-16.
-
(2008)
Lancet Oncol.
, vol.9
, pp. 105-116
-
-
Pfreundschuh, M.1
Schubert, J.2
Ziepert, M.3
-
4
-
-
0037165261
-
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
-
Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-42.
-
(2002)
N Engl J Med.
, vol.346
, pp. 235-242
-
-
Coiffier, B.1
Lepage, E.2
Briere, J.3
-
5
-
-
0027444652
-
The International Non-Hodgkins Lymphoma Prognostic Factors Project
-
A predictive model for aggressive non-Hodgkins lymphoma
-
A predictive model for aggressive non-Hodgkins lymphoma. The International Non-Hodgkins Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-94.
-
(1993)
N Engl J Med.
, vol.329
, pp. 987-994
-
-
-
6
-
-
33847361987
-
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
-
Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857-61.
-
(2007)
Blood
, vol.109
, pp. 1857-1861
-
-
Sehn, L.H.1
Berry, B.2
Chhanabhai, M.3
-
7
-
-
77952477025
-
Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era
-
Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:2373-80.
-
(2010)
J Clin Oncol.
, vol.28
, pp. 2373-2380
-
-
Ziepert, M.1
Hasenclever, D.2
Kuhnt, E.3
-
8
-
-
0022602852
-
Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest Oncology Group experience
-
Dixon DO, Neilan B, Jones SE, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol. 1986;4:295-305.
-
(1986)
J Clin Oncol.
, vol.4
, pp. 295-305
-
-
Dixon, D.O.1
Neilan, B.2
Jones, S.E.3
-
9
-
-
0345131723
-
Elderly patients with aggressive non-Hodgkins lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: Identification of two age subgroups with differing hematologic toxicity
-
Gomez H, Mas L, Casanova L, et al. Elderly patients with aggressive non-Hodgkins lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. J Clin Oncol. 1998;16:2352-8.
-
(1998)
J Clin Oncol.
, vol.16
, pp. 2352-2358
-
-
Gomez, H.1
Mas, L.2
Casanova, L.3
-
10
-
-
0024270189
-
The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkins lymphoma
-
Vose JM, Armitage JO, Weisenburger DD, et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkins lymphoma. J Clin Oncol. 1988;6:1838-44.
-
(1988)
J Clin Oncol.
, vol.6
, pp. 1838-1844
-
-
Vose, J.M.1
Armitage, J.O.2
Weisenburger, D.D.3
-
11
-
-
2642651379
-
Elderly patients with aggressive non-Hodgkins lymphoma: Disease presentation, response to treatment, and survival--a Groupe dEtude des Lymphomes de lAdulte study on 453 patients older than 69 years
-
Bastion Y, Blay JY, Divine M, et al. Elderly patients with aggressive non-Hodgkins lymphoma: disease presentation, response to treatment, and survival--a Groupe dEtude des Lymphomes de lAdulte study on 453 patients older than 69 years. J Clin Oncol. 1997;15:2945-53.
-
(1997)
J Clin Oncol.
, vol.15
, pp. 2945-2953
-
-
Bastion, Y.1
Blay, J.Y.2
Divine, M.3
-
12
-
-
41549137352
-
Non-Hodgkins lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome
-
Thieblemont C, Grossoeuvre A, Houot R, et al. Non-Hodgkins lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol. 2008;19:774-9.
-
(2008)
Ann Oncol.
, vol.19
, pp. 774-779
-
-
Thieblemont, C.1
Grossoeuvre, A.2
Houot, R.3
-
13
-
-
34249293980
-
Racial differences in the incidence and outcomes for patients with hematological malignancies
-
Flowers CR, Glover R, Lonial S, et al. Racial differences in the incidence and outcomes for patients with hematological malignancies. Curr Probl Cancer. 2007;31:182-201.
-
(2007)
Curr Probl Cancer.
, vol.31
, pp. 182-201
-
-
Flowers, C.R.1
Glover, R.2
Lonial, S.3
-
14
-
-
80052042959
-
Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States
-
Dec 22 [Epub ahead of print]
-
Shenoy PJ, Malik N, Nooka A, et al. Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer. 2010;Dec 22 [Epub ahead of print].
-
(2010)
Cancer
-
-
Shenoy, P.J.1
Malik, N.2
Nooka, A.3
-
15
-
-
79251536246
-
Black/white differences in the treatment and outcomes of diffuse large B cell lymphoma: A matched cohort analysis
-
abstr 1392
-
Shenoy PJ, Bumpers K, King N, et al. Black/white differences in the treatment and outcomes of diffuse large B cell lymphoma: a matched cohort analysis. ASH Annual Meeting Abstracts 2009;114:abstr 1392.
-
(2009)
ASH Annual Meeting Abstracts
, vol.114
-
-
Shenoy, P.J.1
Bumpers, K.2
King, N.3
-
16
-
-
0037142053
-
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
-
Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-47.
-
(2002)
N Engl J Med.
, vol.346
, pp. 1937-1947
-
-
Rosenwald, A.1
Wright, G.2
Chan, W.C.3
-
17
-
-
0034598746
-
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
-
Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-11.
-
(2000)
Nature
, vol.403
, pp. 503-511
-
-
Alizadeh, A.A.1
Eisen, M.B.2
Davis, R.E.3
-
18
-
-
54049147790
-
Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP
-
Rimsza LM, LeBlanc ML, Unger JM, et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2008;112:3425-33.
-
(2008)
Blood
, vol.112
, pp. 3425-3433
-
-
Rimsza, L.M.1
LeBlanc, M.L.2
Unger, J.M.3
-
19
-
-
0141672946
-
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma
-
Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198:851-62.
-
(2003)
J Exp Med.
, vol.198
, pp. 851-862
-
-
Rosenwald, A.1
Wright, G.2
Leroy, K.3
-
20
-
-
57149089307
-
Stromal gene signatures in large-B-cell lymphomas
-
Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359:2313-23.
-
(2008)
N Engl J Med.
, vol.359
, pp. 2313-2323
-
-
Lenz, G.1
Wright, G.2
Dave, S.S.3
-
21
-
-
9144237554
-
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
-
Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275-82.
-
(2004)
Blood
, vol.103
, pp. 275-282
-
-
Hans, C.P.1
Weisenburger, D.D.2
Greiner, T.C.3
-
22
-
-
68549124173
-
A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy
-
Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15:5494-502.
-
(2009)
Clin Cancer Res.
, vol.15
, pp. 5494-5502
-
-
Choi, W.W.1
Weisenburger, D.D.2
Greiner, T.C.3
-
23
-
-
79951990286
-
Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab
-
Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol. 2011;29:200-7.
-
(2011)
J Clin Oncol.
, vol.29
, pp. 200-207
-
-
Meyer, P.N.1
Fu, K.2
Greiner, T.C.3
-
24
-
-
70349575802
-
Lymphomas with concurrent BCL2 and MYC translocations: The critical factors associated with survival
-
Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009;114:2273-9.
-
(2009)
Blood
, vol.114
, pp. 2273-2279
-
-
Johnson, N.A.1
Savage, K.J.2
Ludkovski, O.3
-
25
-
-
33645791771
-
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: A prospective correlative study
-
Winter JN, Weller EA, Horning SJ, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood. 2006;107:4207-13.
-
(2006)
Blood
, vol.107
, pp. 4207-4213
-
-
Winter, J.N.1
Weller, E.A.2
Horning, S.J.3
-
26
-
-
77950967521
-
Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: A prospective ECOG and Southwest Oncology Group correlative study on E4494
-
Winter JN, Li S, Aurora V, et al. Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494. Clin Cancer Res. 2010;16:2435-42.
-
(2010)
Clin Cancer Res.
, vol.16
, pp. 2435-2442
-
-
Winter, J.N.1
Li, S.2
Aurora, V.3
-
27
-
-
77954752069
-
Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab
-
Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28:3360-5.
-
(2010)
J Clin Oncol.
, vol.28
, pp. 3360-3365
-
-
Barrans, S.1
Crouch, S.2
Smith, A.3
-
28
-
-
84874624115
-
-
National Comprehensive Cancer Network, Inc, 2012
-
Zelenetz AD, Abramson JS, Advani RH, et al. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkins Lymphoma. v.1.2012. National Comprehensive Cancer Network, Inc, 2012.
-
(2012)
NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkins Lymphoma
, vol.1
-
-
Zelenetz, A.D.1
Abramson, J.S.2
Advani, R.H.3
-
29
-
-
64649093421
-
Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkins lymphoma and diffuse large B-cell lymphoma: A systematic review
-
Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkins lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol. 2009;27:1906-14.
-
(2009)
J Clin Oncol.
, vol.27
, pp. 1906-1914
-
-
Terasawa, T.1
Lau, J.2
Bardet, S.3
-
30
-
-
84874626763
-
Prognostic value of 18F-FDG positron emission tomography used for assessment of the first line therapy in 410 diffuse large B-cell lymphoma patients: A daily practice evaluation before and after the prescription of this metabolic imaging technique
-
Ghesquieres H, Ferlay C, Lavergne E, et al. Prognostic value of 18F-FDG positron emission tomography used for assessment of the first line therapy in 410 diffuse large B-cell lymphoma patients: a daily practice evaluation before and after the prescription of this metabolic imaging technique. Blood. 2011;118:3686.
-
(2011)
Blood
, vol.118
, pp. 3686
-
-
Ghesquieres, H.1
Ferlay, C.2
Lavergne, E.3
-
31
-
-
77951638691
-
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma
-
Moskowitz CH, Schoder H, Teruya-Feldstein J, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol. 2010; 28:1896-903.
-
(2010)
J Clin Oncol.
, vol.28
, pp. 1896-1903
-
-
Moskowitz, C.H.1
Schoder, H.2
Teruya-Feldstein, J.3
-
32
-
-
84874643185
-
Interim restaging PET/CT-guided high dose sequential induction therapy with autologous stem cell transplantation (ASCT) does not improve outcome for poor prognosis diffuse large B-cell lymphoma (DLBCL). ClinicalTrials. Gov Identifier: NCT00530179
-
Stewart DA, Kloiber R, Bahlis N, et al: Interim restaging PET/CT-guided high dose sequential induction therapy with autologous stem cell transplantation (ASCT) does not improve outcome for poor prognosis diffuse large B-cell lymphoma (DLBCL). ClinicalTrials. Gov Identifier: NCT00530179. Blood. 2011;118:500.
-
(2011)
Blood
, vol.118
, pp. 500
-
-
Stewart, D.A.1
Kloiber, R.2
Bahlis, N.3
-
33
-
-
77949312595
-
Interim positron emission tomography scans in diffuse large B-cell lymphoma: An independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study
-
Horning SJ, Juweid ME, Schoder H, et al. Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood. 2010;115:775-7.
-
(2010)
Blood
, vol.115
, pp. 775-777
-
-
Horning, S.J.1
Juweid, M.E.2
Schoder, H.3
-
34
-
-
0028793717
-
High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkins lymphoma: A dose-finding pilot study
-
Shipp MA, Neuberg D, Janicek M, et al. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkins lymphoma: a dose-finding pilot study. J Clin Oncol. 1995;13:2916-23.
-
(1995)
J Clin Oncol.
, vol.13
, pp. 2916-2923
-
-
Shipp, M.A.1
Neuberg, D.2
Janicek, M.3
-
35
-
-
0037676141
-
Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate-and high-grade lymphoma: A phase II study of the Southwest Oncology Group (SWOG 9349)
-
Blayney DW, LeBlanc ML, Grogan T, et al. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate-and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol. 2003;21:2466-73.
-
(2003)
J Clin Oncol.
, vol.21
, pp. 2466-2473
-
-
Blayney, D.W.1
LeBlanc, M.L.2
Grogan, T.3
-
36
-
-
10744224285
-
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma
-
Tilly H, Lepage E, Coiffier B, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003;102:4284-9.
-
(2003)
Blood
, vol.102
, pp. 4284-4289
-
-
Tilly, H.1
Lepage, E.2
Coiffier, B.3
-
37
-
-
3242802160
-
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL
-
Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104:634-41.
-
(2004)
Blood
, vol.104
, pp. 634-641
-
-
Pfreundschuh, M.1
Trumper, L.2
Kloess, M.3
-
38
-
-
0033890745
-
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkins lymphoma: Final analysis of the prospective LNH87-2 protocol--a groupe dEtude des lymphomes de lAdulte study
-
Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkins lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe dEtude des lymphomes de lAdulte study. J Clin Oncol. 2000;18:3025-30.
-
(2000)
J Clin Oncol.
, vol.18
, pp. 3025-3030
-
-
Haioun, C.1
Lepage, E.2
Gisselbrecht, C.3
-
39
-
-
0027394689
-
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkins lymphoma
-
Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkins lymphoma. N Engl J Med. 1993;328:1002-6.
-
(1993)
N Engl J Med.
, vol.328
, pp. 1002-1006
-
-
Fisher, R.I.1
Gaynor, E.R.2
Dahlberg, S.3
-
40
-
-
3042813710
-
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL
-
German High-Grade Non-Hodgkin's Lymphoma Study Group
-
Pfreundschuh M, Trümper L, Kloess M, et al; German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104:626-33.
-
(2004)
Blood
, vol.104
, pp. 626-633
-
-
Pfreundschuh, M.1
Trümper, L.2
Kloess, M.3
-
41
-
-
20144369743
-
ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma
-
Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med. 2005;352:1197-205.
-
(2005)
N Engl J Med.
, vol.352
, pp. 1197-1205
-
-
Reyes, F.1
Lepage, E.2
Ganem, G.3
-
42
-
-
0032530342
-
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
-
Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927-32.
-
(1998)
Blood
, vol.92
, pp. 1927-1932
-
-
Coiffier, B.1
Haioun, C.2
Ketterer, N.3
-
43
-
-
0035863406
-
Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkins lymphoma
-
Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkins lymphoma. J Clin Oncol. 2001;19:389-97.
-
(2001)
J Clin Oncol.
, vol.19
, pp. 389-397
-
-
Vose, J.M.1
Link, B.K.2
Grossbard, M.L.3
-
44
-
-
33646004738
-
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group
-
Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379-91.
-
(2006)
Lancet Oncol.
, vol.7
, pp. 379-391
-
-
Pfreundschuh, M.1
Trumper, L.2
Osterborg, A.3
-
45
-
-
42249097618
-
Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients
-
abstr 8009
-
Coiffier B, Feugier P, Mounier N, et al. Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients. J Clin Oncol. 2007;25(18S):abstr 8009.
-
(2007)
J Clin Oncol.
, vol.25
, Issue.18 S
-
-
Coiffier, B.1
Feugier, P.2
Mounier, N.3
-
46
-
-
38449114046
-
CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: Results of the HE22A99 trial of the Hellenic Cooperative Oncology Group
-
Economopoulos T, Psyrri A, Dimopoulos MA, et al. CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: results of the HE22A99 trial of the Hellenic Cooperative Oncology Group. Cancer J. 2007;13:327-34.
-
(2007)
Cancer J.
, vol.13
, pp. 327-334
-
-
Economopoulos, T.1
Psyrri, A.2
Dimopoulos, M.A.3
-
47
-
-
80054750428
-
R-CHOP14 versus R-CHOP21: Result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma
-
abstr 8000
-
Cunningham D, Smith P, Mouncey W, et al. R-CHOP14 versus R-CHOP21: result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma. J Clin Oncol. 2011;29:abstr 8000.
-
(2011)
J Clin Oncol.
, vol.29
-
-
Cunningham, D.1
Smith, P.2
Mouncey, W.3
-
48
-
-
77951805009
-
R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma: Results of the interim analysis of the LNH03-6B GELA study
-
abstr 406
-
Delarue R, Tilley H, Salles G, et al. R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma: results of the interim analysis of the LNH03-6B GELA study. ASH Annual Meeting Abstracts. 2009;114(22):abstr 406.
-
(2009)
ASH Annual Meeting Abstracts.
, vol.114
, Issue.22
-
-
Delarue, R.1
Tilley, H.2
Salles, G.3
-
49
-
-
45749152667
-
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers
-
Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2008;26:2717-24.
-
(2008)
J Clin Oncol.
, vol.26
, pp. 2717-2724
-
-
Wilson, W.H.1
Dunleavy, K.2
Pittaluga, S.3
-
50
-
-
84861392779
-
A cancer and leukemia group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype
-
Dec 1 [Epub ahead of print]
-
Wilson W, Jung SH, Porcu P, et al. A cancer and leukemia group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica. 2011 Dec 1 [Epub ahead of print].
-
(2011)
Haematologica
-
-
Wilson, W.1
Jung, S.H.2
Porcu, P.3
-
51
-
-
12144286396
-
Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support
-
Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med. 2004;350:1287-95.
-
(2004)
N Engl J Med.
, vol.350
, pp. 1287-1295
-
-
Milpied, N.1
Deconinck, E.2
Gaillard, F.3
-
52
-
-
44949229297
-
High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults
-
Greb A, Bohlius J, Schiefer D, et al. High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults. Cochrane Database Syst Rev. 2008;1:CD004024.
-
(2008)
Cochrane Database Syst Rev.
, vol.1
-
-
Greb, A.1
Bohlius, J.2
Schiefer, D.3
-
53
-
-
80052980811
-
Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL)
-
abstr 8001
-
Stiff PJ, Unger JM, Cook J, et al. Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL). J Clin Oncol. 2011;29(suppl):abstr 8001.
-
(2011)
J Clin Oncol.
, vol.29
, Issue.SUPPL.
-
-
Stiff, P.J.1
Unger, J.M.2
Cook, J.3
-
54
-
-
77958453257
-
High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma
-
German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
-
Glass B, Ziepert M, Reiser M, et al; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma. Ann Oncol. 2010;21:2255-61.
-
(2010)
Ann Oncol.
, vol.21
, pp. 2255-2261
-
-
Glass, B.1
Ziepert, M.2
Reiser, M.3
-
55
-
-
79952982718
-
A decade of progress in lymphoma: Advances and continuing challenges
-
Flowers CR, Armitage JO. A decade of progress in lymphoma: advances and continuing challenges. Clin Lymphoma Myeloma Leuk. 2010;10:414-23.
-
(2010)
Clin Lymphoma Myeloma Leuk.
, vol.10
, pp. 414-423
-
-
Flowers, C.R.1
Armitage, J.O.2
|